Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Arcturus Therapeutics yesterday and set a price target of $66.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Whitney Ijem has given his Buy rating due to a combination of factors surrounding Arcturus Therapeutics’ recent developments and future prospects. The company’s 2Q25 report provided promising updates, particularly regarding the ARCT-032 program for cystic fibrosis, which is progressing with data expected to be released earlier than anticipated. This data includes results from the first nine participants treated with daily inhaled doses, with further dosing and regulatory engagements planned.
Additionally, Arcturus’ financial health remains robust with a substantial cash reserve, supporting its ongoing projects. The company also maintains its momentum in other areas such as its vaccine programs, which are on track. These factors, along with strategic adjustments in revenue expectations for future products, underpin Ijem’s confidence in the stock’s potential, justifying the Buy rating with a price target of $66.
Ijem covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Taysha Gene Therapies, and Vertex Pharmaceuticals. According to TipRanks, Ijem has an average return of 17.7% and a 48.72% success rate on recommended stocks.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $49.00 price target.